Knight Therapeutics (TSE:GUD) Sets New 52-Week High – What’s Next?

Knight Therapeutics Inc. (TSE:GUD)’s share price hit a new 52-week high on Friday. The stock traded as high as C$12.19 and last traded at C$12.03, with a volume of 39,122 shares traded. The stock had previously closed at C$12.05.

Knight Therapeutics Stock Performance

The company has a debt-to-equity ratio of 4.22, a current ratio of 2.40 and a quick ratio of 1.79. The company has a market cap of C$1.18 billion, a price-to-earnings ratio of 75.12, a PEG ratio of -1,013.50 and a beta of -0.51. The firm has a 50 day simple moving average of C$10.79 and a 200-day simple moving average of C$8.79.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings results on Thursday, November 5th. The company reported C($0.03) EPS for the quarter. The business had revenue of C$136.74 million during the quarter. Knight Therapeutics had a net margin of 2.84% and a return on equity of 2.03%. As a group, analysts predict that Knight Therapeutics Inc. will post 0.10 EPS for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.